Novartis

Novartis(NVSEF)

BASEL, Switzerland
Pharmaceutical2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules, Vaccines, Biologics / Diagnostics

Novartis is a life sciences company focused on Small Molecules, Vaccines, Biologics / Diagnostics.

OncologyImmunologyNeuroscienceCardiovascularOphthalmology
Funding Stage
PUBLIC
Employees
78,000
Open Jobs
646

Products & Portfolio (29)

21 discontinued products not shown

ACETAMINOPHEN
acetaminophen
Post-LOE
INTRAVENOUS · SOLUTION
12.1 Mechanism of Action The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions. 12.2 Pharmacodynamics Acetaminophen has been shown to have analgesic and antipyretic activities in animal and human studies. Single doses of acetaminophen up to 3000 mg and repeated doses of 1000 mg every 6 hours for 48 hours have not been shown to cause a significant effect on platelet aggregation. Acetaminophen does not have any immediate or delayed effects on small-vessel hemostasis. Clinical studies of both healthy subjects and patients with hemophilia showed no significant changes in bleeding time after receiving multiple doses of oral acetaminophen. 12.3 Pharmacokinetics Distribution The pharmacokinetics of acetaminophen have been studied in patients and healthy subjects up to 60 years old. The pharmacokinetic profile of acetaminophen has been demonstrated to be dose proportional in adults following administration of single doses of 500, 650, and 1000 mg. The maximum concentration (C max ) occurs at the end of the 15 minute intravenous infusion of acetaminophen. Compared to the same dose of oral acetaminophen, the C max following administration of acetaminophen is up to 70% higher, while overall exposure (area under the concentration time curve [AUC]) is very similar. Pharmacokinetic parameters of acetaminophen (AUC, C max , terminal elimination half-life [T ½ ], systemic clearance [CL], and volume of distribution at steady state [V ss ]) following administration of a single intravenous dose of 15 mg/kg in children and adolescents and 1000 mg in adults are summarized in Table 5 . Table 5. Acetaminophen Pharmacokinetic Parameters Subpopulations Mean (SD) AUC 0-6h (mcg × h/mL) C max (mcg/mL) T ½ (h) CL (L/h/kg) V ss (L/kg) Children 38 (8) 29 (7) 3 (1.5) 0.34 (0.10) 1.2 (0.3) Adolescents 41 (7) 31 (9) 2.9 (0.7) 0.29 (0.08) 1.1 (0.3) Adults 43 (11) 28 (21) 2.4 (0.6) 0.27 (0.08) 0.8 (0.2) The concentrations of acetaminophen observed in neonates greater than 32 weeks gestational age at birth treated with 12.5 mg/kg dose are similar to infants, children and adolescents treated with a 15 mg/kg dose, and similar to adults treated with a 1000 mg dose. At therapeutic levels, binding of acetaminophen to plasma proteins is low (ranging from 10% to 25%). Acetaminophen appears to be widely distributed throughout most body tissues except fat. Metabolism and Excretion Acetaminophen is primarily metabolized in the liver by first-order kinetics and involves three principal separate pathways: Conjugation with glucuronide, conjugation with sulfate, and oxidation via the cytochrome P450 enzyme pathway, primarily CYP2E1, to form a reactive intermediate metabolite (N-acetyl-p-benzoquinone imine or NAPQI). With therapeutic doses, NAPQI undergoes rapid conjugation with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates. Acetaminophen metabolites ar
mild to moderate pain in adultoldermoderate to severe pain with adjunctive opioid analgesics in adult+2 more
2016
30
ADAKVEO
crizanlizumab
Peak
mAbINJECTION · INJECTABLE
P-Selectin Blockers
frequency of vasoocclusive crises in adultsolder with sickle cell disease
2019
30
AFATINIB
afatinib
Pre-Launch
TABLET
(ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L858R substitutions and exon 19 deletions. Afatinib demonstrated inhibition of autophosphorylation and/or in vitro proliferation of cell lines expressing wild-type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at afatinib concentrations achieved in patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2. Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
lung cancer
AFINITOR
everolimus
LOE Approaching
ORAL · TABLET
Protein Kinase Inhibitors
older with TSCpostmenopausal women with advanced hormone receptor-positiveHER2-negative breast cancer in combination with exemestane+12 more
2009
30
AFINITOR DISPERZ
everolimus
Peak
ORAL · TABLET, FOR SUSPENSION
Protein Kinase Inhibitors
older with TSCpostmenopausal women with advanced hormone receptor-positiveHER2-negative breast cancer in combination with exemestane+12 more
2012
45
ALBUTEROL SULFATE
albuterol sulfate
Post-LOE
INHALATION · AEROSOL, METERED
Mechanism of Action In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50% of cardiac beta-adrenergic receptors. The precise function of these receptors has not been established. (See section.) Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP). This increase of cyclic AMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.
children 4 years of ageolder for the treatmentprevention of bronchospasm with reversible obstructive airway disease+1 more
2021
30
ALPRAZOLAM
alprazolam
Post-LOE
ORAL · TABLET
1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
panic disorder (PD)withwithout agoraphobia in adults+2 more
1998
30
ALPRAZOLAM
alprazolam
Post-LOE
ORAL · TABLET
1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
panic disorder (PD)withwithout agoraphobia in adults+2 more
1995
30
AMANTADINE HYDROCHLORIDE
amantadine hydrochloride
Post-LOE
ORAL · CAPSULE
CLINICAL PHARMACOLOGY Pharmacodynamics Mechanism of Action Antiviral The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. Antiviral Activity Amantadine inhibits the replication of influenza A virus isolates from each of the subtypes, i.e., H1N1, H2N2 and H3N2. It has very little or no activity against influenza B virus isolates. A quantitative relationship between the in vitro susceptibility of influenza A virus to amantadine and the clinical response to therapy has not been established in man. Sensitivity test results, expressed as the concentration of amantadine required to inhibit by 50% the growth of virus (ED 50 ) in tissue culture vary greatly (from 0.1 mcg/mL to 25 mcg/mL) depending upon the assay protocol used, size of virus inoculum, isolates of influenza A virus strains tested, and the cell type used. Host cells in tissue culture readily tolerated amantadine up to a concentration of 100 mcg/mL. Drug Resistance Influenza A variants with reduced in vitro sensitivity to amantadine have been isolated from epidemic strains in areas where adamantane derivatives are being used. Influenza viruses with reduced in vitro sensitivity have been shown to be transmissible and to cause typical influenza illness. The quantitative relationship between the in vitro sensitivity of influenza A variants to amantadine and the clinical response to therapy has not been established. Mechanism of Action Parkinson's Disease The mechanism of action of amantadine hydrochloride in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (Ki = 10μM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Pharmacokinetics Amantadine Hydrochloride is well absorbed orally. Maximum plasma concentrations are directly related to dose for doses up to 200 mg/day. Doses above 200 mg/day may result in a greater than proportional increase in maximum plasma concentrations. It is primarily excreted unchanged in the urine by glomerular filtration and tubular secretion. Eight metabolites of amantadine have been identified in human urine. One metabolite, an N-acetylated compound, was quantified in human urine and accounted for 5 to 15% of the administered dos
the treatment of parkinsonismdrug-induced extrapyramidal reactionsthe treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially+9 more
1987
30
AMITRIPTYLINE HYDROCHLORIDE
amitriptyline hydrochloride
Post-LOE
ORAL · TABLET
CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
depression
1977
30
AMITRIPTYLINE HYDROCHLORIDE
amitriptyline hydrochloride
Post-LOE
ORAL · TABLET
CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
depression
1977
30
AMOXICILLIN
amoxicillin
Post-LOE
ORAL · TABLET
[see Microbiology ()].
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus speciesthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli+3 more
2005
30
View all 29 products

Pipeline & Clinical Trials

sacubitril/valsartan
Heart Failure
N/A
Clinical Trials (5)
NCT02690974Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
Phase 4
NCT02788656Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
Phase 4
NCT03119623Comparing ARNI With ACE Inhibitor on Endothelial Function
Phase 4

+2 more

3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix
Presbyopia
N/A
Clinical Trials (1)
NCT02965833CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers
N/A
N/A
Clinical Trials (5)
NCT05935215Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3
NCT05755386Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3
NCT04889430Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Phase 3

+2 more

NewSpringForMe digital solution
Hematologic Diseases
N/A
Lutetium-177 DOTATATE
Neuroendocrine Tumor
N/A
Clinical Trials (1)
NCT05816720Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
N/A
Analysis of the Time Taken to Triple Therapy (NOVARTIS)
COPD
N/A
Clinical Trials (1)
NCT01786720Analysis of the Time Taken to Triple Therapy (NOVARTIS)
N/A
N/A
Clinical Trials (5)
NCT03623243Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Phase 3
NCT04895202Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
N/A
NCT05376579Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
N/A

+2 more

Patient-oriented educational intervention
Acute Coronary Syndromes
N/A
Clinical Trials (1)
NCT07252388EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention
N/A
Bridging Radiotherapy
Diffuse Large B Cell Lymphoma
N/A
Clinical Trials (1)
NCT04726787RadiothErapy priMIng for CAR-T
N/A
Fabhalta Capsules Specified Drug-use Survey
C3 Glomerulopathy
N/A
Clinical Trials (1)
NCT07156149Fabhalta Capsules Specified Drug-use Survey
N/A
ranibizumab
Glaucoma
N/A
Clinical Trials (1)
NCT00892398Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab
N/A
N/A
Clinical Trials (1)
NCT02126904Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept
N/A
ITP Registry and Accompanying Biospecimen Collection
Immune Thrombocytopenia
N/A
N/A
Clinical Trials (1)
NCT00413270Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
N/A
N/A
Clinical Trials (5)
NCT01469884Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients
Phase 4
NCT02254668Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography
Phase 4
NCT00154297Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
Phase 4

+2 more

N/A
Clinical Trials (1)
NCT00507273Gastrointestinal Stromal Tumors (GIST) Registry
N/A
Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT01272596Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis
N/A
Cardiopulmonary exercise test
Prior Acute Myocardial Infarction
N/A
Clinical Trials (1)
NCT01900600Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
N/A
N/A
Clinical Trials (5)
NCT00310687Persistence of Immune Response After Vaccination With MCC
Phase 4
NCT00452621Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
Phase 4
NCT01562444Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Phase 4

+2 more

N/A
Clinical Trials (1)
NCT06411626Home Reported Outcomes in PNH
N/A
Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
Alport Syndrome
N/A
Clinical Trials (1)
NCT01602835Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
N/A
Treatment
Cancer
N/A
Clinical Trials (5)
NCT00104442Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Phase 4
NCT00139594Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Phase 4
NCT01056822Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
Phase 4

+2 more

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With O
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT06460324A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
N/A
ribociclib + ET
Breast Cancer
N/A
Clinical Trials (1)
NCT05697146Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
N/A
N/A
Clinical Trials (1)
NCT05526729Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
N/A
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatm
Cardiovascular Disease
N/A
Clinical Trials (1)
NCT07214857Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
N/A
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Surve
Dry Eye Disease
N/A
Clinical Trials (1)
NCT06018571Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
N/A
Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
Alport Nephropathy
N/A
Clinical Trials (1)
NCT03074357Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
N/A
tobacco smoking substitution products
HIV
N/A
Clinical Trials (1)
NCT06789692Reduce Tobacco Use in People Living With HIV in Switzerland
N/A
Ribociclib
Breast Cancer
N/A
Clinical Trials (1)
NCT06905301Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
N/A
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-wo
Moderate-to-severe Plaque Psoriasis
N/A
Clinical Trials (1)
NCT05787236A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
N/A
other disease-modifying therapy
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT01442194Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
N/A
N/A
Clinical Trials (5)
NCT02445222CAR-T Long Term Follow Up (LTFU) Study
Phase 3
NCT05172596PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase 2
NCT04318327BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1

+2 more

Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT02592265Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden
N/A
N/A
Clinical Trials (1)
NCT05293470A Post Marketing Surveillance on Piqray in Korea
N/A
N/A
Clinical Trials (3)
NCT05407740"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease
N/A
NCT04948671Primary Hyperparathyroidism and Gut Microbiota
N/A
NCT06637657Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
N/A
N/A
Clinical Trials (5)
NCT00784485Non-invasive Measures of Effects of Xolair in Asthma
Phase 4
NCT04648930Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
N/A
NCT05626257Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps
N/A

+2 more

dabrafenib + trametinib
Malignant Melanoma
N/A
Clinical Trials (3)
NCT02974803Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Phase 2
NCT04547946Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
N/A
NCT05848219Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
N/A
No intervention
Kidney Diseases
N/A
Clinical Trials (1)
NCT06851845Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study
N/A
N/A
Clinical Trials (1)
NCT02624570Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
N/A
real anodal transcranial direct current stimulation
Real tDCS
N/A
Clinical Trials (1)
NCT03959462Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals
N/A
N/A
Clinical Trials (5)
NCT03340506Dabrafenib and/or Trametinib Rollover Study
Phase 4
NCT03975829Pediatric Long-Term Follow-up and Rollover Study
Phase 4
NCT01597908Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Phase 3

+2 more

A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
Acute Lymphoblastic Leukemia
N/A
Clinical Trials (1)
NCT07039383A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
N/A
Swiss Severe Asthma Register
Severe Asthma
N/A
N/A
Clinical Trials (5)
NCT00149994Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
Phase 4
NCT00150085Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion
Phase 4
NCT00821587Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
Phase 4

+2 more

Studied cohort
Diabetic Retinopathy
N/A
Clinical Trials (1)
NCT02232503Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
N/A
N/A
Clinical Trials (1)
NCT05529862Trans-RosaLEE Study: a Biomarker-directed, Translational Study
N/A
N/A
Clinical Trials (5)
NCT02232061Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
Phase 4
NCT04480853Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Phase 4
NCT01333501Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Phase 4

+2 more

Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Pso
Psoriasis
N/A
Clinical Trials (1)
NCT00098189Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
N/A
Control group
Osteoporosis
N/A

Open Jobs (646)

ED, CRM Product Owner, Data & AI

East Hanover
Yesterday
$237K - $439K/yr

Access Strategy Manager

Bogota (Pharmaceuticals / GDD / NTO / CTS)
Yesterday

Access Strategy Manager

Bogota (Pharmaceuticals / GDD / NTO / CTS)
Yesterday

Ultra-Rare Disease Territory Account Specialist – Denver, CO

Field Sales (USA)
Yesterday
$132K - $246K/yr

Research Scientist II

Basel (City)
Yesterday

Director, Market Access Strategy - Cell Therapy

Remote
Yesterday
$195K - $361K/yr

Manager - Vendor Business Office

Hyderabad (Office)
Yesterday

Global ESG (Environmental Social Governance) Risk & Controls Manager

Home Worker
Yesterday

Senior Technical Manager (MS&T), ESO

Hyderabad (Office)
Yesterday

Director PSL - CAR-T Immunology

East Hanover
Yesterday
$186K - $345K/yr

Ultra-Rare Area Business Leader – Northwest

Field Sales (USA)
Yesterday
$168K - $312K/yr

Senior Manager, Regulatory Affairs CMC

Schaftenau
Yesterday

Ultra-Rare Disease Territory Account Specialist – Phoenix, AZ

Field Sales (USA)
Yesterday
$132K - $246K/yr

SSO Study Start-Up Manager

Israel
Yesterday

Cardiovascular Territory Account Specialist –Oklahoma City, OK-North

Field Sales (USA)
Yesterday
$120K - $222K/yr

Director, Launch Excellence Strategy (1 of 2)

East Hanover
Yesterday
$186K - $345K/yr

Technical Manager (MS&T) ESO

Hyderabad (Office)
Yesterday

Senior Scientist, Lead Identification and Optimization (LIDO)

Cambridge (USA)
2d ago
$94K - $174K/yr

Data Analyst – Marketing Automation Platforms

Hyderabad (Office)
2d ago

Principal Scientist, BMD Study Coordinator and BMD Study Expert (BSC/BSE) Biomarkers

Hyderabad (Office)
2d ago

Expert Science & Technology- Oral Solid Dosage

Hyderabad (Office)
2d ago

Manager nabave (m/ž/d) / Procurement Manager (m/f/d)

Ljubljana
2d ago

Sr Analyst - Data Science

Hyderabad (Office)
2d ago

Manager-Payer MDM

Hyderabad (Office)
2d ago

Quality Team Leader QC (m/f/d)

Schaftenau
2d ago
View all 646 open positions →
Interview Prep Quick Facts
Portfolio: 699 approved products, 193 clinical trials
Top TAs: Oncology, Cardiovascular, Infectious Diseases
H-1B (2023): 2 approvals
Publications: 25 in PubMed
Open Roles: 646 active jobs
Portfolio Health
Pre-Launch87 (12%)
Launch2 (0%)
Growth9 (1%)
Peak39 (6%)
LOE Approaching179 (26%)
Post-LOE383 (55%)
699 total products
Therapeutic Area Focus
Oncology
46 marketed1582 pipeline
Cardiovascular
55 marketed393 pipeline
Infectious Diseases
29 marketed285 pipeline
Neurology
31 marketed282 pipeline
Respiratory
11 marketed271 pipeline
Nephrology
8 marketed234 pipeline
Immunology
22 marketed190 pipeline
Metabolic Diseases
4 marketed207 pipeline
Marketed
Pipeline

Hiring Trend

Actively Hiring
646
Open Roles
+736
Added
-72
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub